Home The Word Brain	My Amedeo FAQ Privacy About
	Amedeo C49 English + 你好 (nǐ hǎo) = limitless possibilities. Start learning Mandarin Chinese today—for free, forever. Amedeo C49 is completely free, for life. Next week: +49.

Chronic Heart Failure

Free Subscription 08.09.2025 4 Am J Cardiol 3 Circ Heart Fail 2 Circulation 1 Clin Cardiol 8 Eur Heart J 3 Eur J Heart Fail 1 Heart 4 Int J Cardiol 12 J Am Coll Cardiol 3 J Card Fail 1 J Cardiol 1 J Mol Cell Cardiol 9 Lancet 1 N Engl J Med 3 PLoS One

Retrieve available abstracts of this week’s articles: HTML format

Single Articles

Am J Cardiol

1. SCRUTINIO D, Guida P, Passantino A
   Interaction of risk of death and improvement in functional capacity after cardiac rehabilitation on Heart Failure prognosis.
   Am J Cardiol. 2025 Sep 3:S0002-9149(25)00517.
   PubMed         Abstract available
   
   
2. SILVESTRE J, Brgdar A, Chen J, Di Salvo TG, et al
   Increasing Rate of Unfilled Training Positions in the Advanced Heart Failure and Transplant Cardiology Match.
   Am J Cardiol. 2025 Sep 2:S0002-9149(25)00511.
   PubMed         Abstract available
   
   
3. KELLEY GA, Kelley KS, Stauffer BL
   Representation of Heart Failure Patients According to Age, Sex, and Race in US-Based Exercise Trials: A Systematic Review with Meta-Analysis of Randomized Trials.
   Am J Cardiol. 2025 Sep 2:S0002-9149(25)00532.
   PubMed        
   
   
4. QUINTANA-HAYASHI MP, Connolly K, Greasley P, Chan M, et al
   A Phase 1b Randomized Clinical Trial of AZD5642 and Dapagliflozin in Patients with Heart Failure and Moderate Renal Impairment.
   Am J Cardiol. 2025 Sep 2:S0002-9149(25)00510.
   PubMed         Abstract available
   
   

   
   Circ Heart Fail

5. MARGARYAN R, Sepehrvand N, Ouwerkerk W, Tromp J, et al
   Network Meta-Analysis of Quality of Life in Heart Failure With Reduced Ejection Fraction.
   Circ Heart Fail. 2025 Sep 5:e013074. doi: 10.1161/CIRCHEARTFAILURE.125.013074.
   PubMed         Abstract available
   
   
6. LAUFER-PERL M, Flint N, Arbel Y, Alenezi F, et al
   Atrial Mechanics in Heart Failure With Preserved Ejection Fraction: Effect of a No-Implant Interatrial Shunt.
   Circ Heart Fail. 2025 Sep 3:e012573. doi: 10.1161/CIRCHEARTFAILURE.124.012573.
   PubMed         Abstract available
   
   
7. SKAARUP KG, Johansen ND, Modin D, Loiacono MM, et al
   High-Dose vs. Standard-Dose Influenza Vaccine in Heart Failure: A Prespecified Analysis of the DANFLU-2 Trial.
   Circ Heart Fail. 2025 Aug 30. doi: 10.1161/CIRCHEARTFAILURE.125.013678.
   PubMed         Abstract available
   
   

   
   Circulation

8. SOHNS C, Moersdorf M, Marrouche NF, Costard-Jaeckle A, et al
   3-Year Outcomes of Catheter Ablation in Patients with End-Stage Heart Failure and Atrial Fibrillation.
   Circulation. 2025 Aug 31. doi: 10.1161/CIRCULATIONAHA.125.075787.
   PubMed        
   
   
9. BERG DD, Patel SM, Haller PM, Cange AL, et al
   Dapagliflozin in Patients Hospitalized for Heart Failure: Primary Results of the DAPA ACT HF-TIMI 68 Randomized Clinical Trial and Meta-Analysis of Sodium-Glucose Cotransporter-2 Inhibitors in Patients Hospitalized for Heart Failure.
   Circulation. 2025 Aug 29. doi: 10.1161/CIRCULATIONAHA.125.076575.
   PubMed         Abstract available
   
   

   
   Clin Cardiol

10. GUPTA R, Vohra S, Yadav A, Gupta N, et al
    Methodological and Statistical Concerns Regarding "Can Sodium-Glucose Co-Transporter-2 Inhibitors Improve Sleep Quality, Anxiety, and Quality of Life in Patients With Heart Failure?".
    Clin Cardiol. 2025;48:e70203.
    PubMed        
    
    

    
    Eur Heart J

11. BUTLER J, Fioretti F, McMullan CJ, Anstrom KJ, et al
    Vericiguat and mortality in heart failure and reduced ejection fraction: the VICTOR trial.
    Eur Heart J. 2025 Aug 30:ehaf655. doi: 10.1093.
    PubMed         Abstract available
    
    
12. ANKER MS, Mahabadi AA, Totzeck M, Tewes M, et al
    Heart Failure Therapy in Patients with Advanced Cancer Receiving Specialized Palliative Care (EMPATICC trial).
    Eur Heart J. 2025 Aug 30:ehaf705. doi: 10.1093.
    PubMed         Abstract available
    
    
13. BORLAUG BA, Zile MR, Kramer CM, Litwin SE, et al
    HFpEF-ABA score is a more useful enrichment tool than natriuretic peptides in heart failure with preserved ejection fraction.
    Eur Heart J. 2025 Aug 31:ehaf663. doi: 10.1093.
    PubMed        
    
    
14. CHIMURA M, Docherty KF, Jhund PS, Yang M, et al
    Serum magnesium and outcomes in heart failure with reduced ejection fraction: the GALACTIC-HF trial.
    Eur Heart J. 2025 Aug 31:ehaf706. doi: 10.1093.
    PubMed         Abstract available
    
    
15. BUTT JH, Solomon SD, McMurray JJV
    Incretin-based therapy for heart failure with reduced ejection fraction: why we need a trial.
    Eur Heart J. 2025 Sep 1:ehaf635. doi: 10.1093.
    PubMed        
    
    
16. PACKER M
    Do obesity and visceral adiposity promote heart failure with reduced ejection fraction?
    Eur Heart J. 2025 Sep 2:ehaf645. doi: 10.1093.
    PubMed         Abstract available
    
    
17. PEIKERT A, Fontana M, Solomon SD, Thum T, et al
    Left ventricular hypertrophy and myocardial fibrosis in heart failure with preserved ejection fraction: mechanisms and treatment.
    Eur Heart J. 2025 Sep 2:ehaf524. doi: 10.1093.
    PubMed         Abstract available
    
    
18. INKER LA, Neuen BL, McCallum W, Vaduganathan M, et al
    Decline in glomerular filtration rate as an endpoint in heart failure clinical trials: challenges and solutions.
    Eur Heart J. 2025 Sep 4:ehaf591. doi: 10.1093.
    PubMed         Abstract available
    
    

    
    Eur J Heart Fail

19. AIMO A, Vergaro G, Pastore MC, Tomasoni D, et al
    High prevalence of wild-type transthyretin cardiac amyloidosis in older adults with carpal tunnel syndrome, heart failure or increased left ventricular mass: The CAPTURE study.
    Eur J Heart Fail. 2025 Sep 1. doi: 10.1002/ejhf.70030.
    PubMed        
    
    
20. BUNTING KV, Champsi A, Gill SK, Saadeh K, et al
    Low-dose digoxin improves cardiac function in patients with heart failure, preserved ejection fraction and atrial fibrillation - the RATE-AF randomized trial.
    Eur J Heart Fail. 2025 Sep 2. doi: 10.1002/ejhf.70022.
    PubMed         Abstract available
    
    
21. REIMER JENSEN AM, Ross JC, Arthur V, Hall ME, et al
    Integrated trajectories of systolic and diastolic function differentially associate with risk for heart failure with preserved and reduced ejection fraction and proteomic profiles.
    Eur J Heart Fail. 2025 Sep 2. doi: 10.1002/ejhf.70015.
    PubMed         Abstract available
    
    

    
    Heart

22. RAHIMI K, Gerdts E
    Beyond hypertension: quantifying the full risk landscape for heart failure in women.
    Heart. 2025 Sep 3:heartjnl-2025-326874. doi: 10.1136/heartjnl-2025-326874.
    PubMed        
    
    

    
    Int J Cardiol

23. ATIF MM, Lohano G, Ram M, Irshad NUN, et al
    Letter to the editor: Outcomes in patients undergoing trans-catheter edge-to-edge mitral valve repair as compared to a general and heart failure population.
    Int J Cardiol. 2025;440:133699.
    PubMed        
    
    
24. PANG X, Zhao S, Zhang F
    Comment on: "Outcomes in patients undergoing transcatheter edge-to-edge mitral valve repair as compared to a general and heart failure population".
    Int J Cardiol. 2025;440:133698.
    PubMed        
    
    
25. NOIRI JI, Tanaka H
    Authors' reply to Zhang et al. regarding "Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population".
    Int J Cardiol. 2025 Aug 28:133840. doi: 10.1016/j.ijcard.2025.133840.
    PubMed        
    
    
26. ZHANG L, Luo Z, Lin R
    Comment on "Efficacy of sodium-glucose cotransporter 2 inhibitors for super-aged heart failure population".
    Int J Cardiol. 2025 Aug 28:133841. doi: 10.1016/j.ijcard.2025.133841.
    PubMed        
    
    

    
    J Am Coll Cardiol

27. SKAARUP KG, Lassen MCH, Johansen ND, Christensen SH, et al
    Effect of RSV Vaccine on Heart Failure Hospitalizations: A Prespecified Analysis of the DAN-RSV Trial.
    J Am Coll Cardiol. 2025 Aug 26:S0735-1097(25)07467.
    PubMed        
    
    
28. PACKER M
    The Adipokine Hypothesis of Heart Failure With a Preserved Ejection Fraction: A Novel Framework to Explain Pathogenesis and Guide Treatment.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07049.
    PubMed         Abstract available
    
    
29. VAN ESSEN BJ, Ceelen DCH, Ouwerkerk W, Teng TK, et al
    Pharmacological Treatment of Heart Failure with Reduced Ejection Fraction: An Updated Systematic Review and Network Meta-Analysis.
    J Am Coll Cardiol. 2025 Aug 26:S0735-1097(25)07572.
    PubMed         Abstract available
    
    
30. ZANNAD F, Reddy YNV, Barash I, Anstrom KJ, et al
    Effect of Vericiguat on Worsening Heart Failure in Compensated Outpatients with HFrEF: Insights from VICTOR.
    J Am Coll Cardiol. 2025 Aug 21:S0735-1097(25)07559.
    PubMed         Abstract available
    
    
31. OSTROMINSKI JW, Neuen BL, Claggett BL, Anand IS, et al
    Natriuretic Peptides, Body Mass Index, and Clinical Outcomes in Heart Failure with Mildly Reduced or Preserved Ejection Fraction.
    J Am Coll Cardiol. 2025 Aug 19:S0735-1097(25)07493.
    PubMed         Abstract available
    
    
32. PACKER M, Zile MR, Kramer CM, DiMaria JM, et al
    Influence of Type 2 Diabetes on the Effects of Tirzepatide in Patients With Heart Failure and a Preserved Ejection Fraction With Obesity: A Prespecified Stratification-Based Analysis.
    J Am Coll Cardiol. 2025;86:696-707.
    PubMed         Abstract available
    
    
33. SAVARESE G, Butler J
    Incretin-Based Therapies and Heart Failure Outcomes: Benefit Beyond Weight Loss?
    J Am Coll Cardiol. 2025;86:708-710.
    PubMed        
    
    
34. HUANG X, Hughes Z, Fonarow GC, Ahmad FS, et al
    Racial and Ethnic Differences in Patient Age at First Hospitalization for Heart Failure.
    J Am Coll Cardiol. 2025;86:711-720.
    PubMed         Abstract available
    
    
35. GANGAVELLI A, Steinberg RS, Johnson AE, Ogunniyi MO, et al
    Advancing Equity in Heart Failure Outcomes: From Social Context to Structural Solutions.
    J Am Coll Cardiol. 2025;86:721-724.
    PubMed        
    
    
36. KITAI T, Kanaoka K, Shoji S, Tsugawa Y, et al
    Heart Failure in the Oldest-Old: A Growing Clinical and Economic Burden in Aging Japan.
    J Am Coll Cardiol. 2025;86:757-760.
    PubMed        
    
    
37. LEE AY, Palaniappan L, Rana JS, Lombardo D, et al
    Time to Disaggregate "Asian American" to Address Disparities in Heart Failure Risk.
    J Am Coll Cardiol. 2025;86:735-737.
    PubMed        
    
    
38. AMBROSY AP, Daida YG, Parikh RV, Tan TC, et al
    Incidence of Heart Failure in Asian American, Native Hawaiian, and Other Pacific Islander Populations.
    J Am Coll Cardiol. 2025;86:725-734.
    PubMed         Abstract available
    
    

    
    J Card Fail

39. VENEMA CS, Metra M, Staal L, Beldhuis IE, et al
    Impact of Mild and Moderate Aortic Stenosis in Acute Heart Failure: Insights from RELAX-AHF-2.
    J Card Fail. 2025 Aug 14:S1071-9164(25)00338.
    PubMed         Abstract available
    
    
40. KITAI T, Kohsaka S, Kato T, Kato E, et al
    JCS/JHFS 2025 Guideline on Diagnosis and Treatment of Heart Failure.
    J Card Fail. 2025 Sep 1:S1071-9164(25)00328.
    PubMed        
    
    
41. O'CONNOR CM, Rathwell S, Mehrotra DV, Corda S, et al
    Assessing Benefit in Heart Failure Patients with Reduced Ejection Fraction: Analysis of the VICTORIA Trial Using Novel Prognostic Risk Stratification.
    J Card Fail. 2025 Aug 28:S1071-9164(25)00373.
    PubMed         Abstract available
    
    

    
    J Cardiol

42. FUJIMOTO N, Omori T, Moriwaki K, Nakamori S, et al
    Pressure-volume loop analysis in heart failure with preserved ejection fraction: Implications for cardiac mechanics, diagnosis, and treatment strategy.
    J Cardiol. 2025 Aug 28:S0914-5087(25)00215-1. doi: 10.1016/j.jjcc.2025.
    PubMed         Abstract available
    
    

    
    J Mol Cell Cardiol

43. CHEN D, Sindone A, Huang MLH, Peter K, et al
    Diabetic cardiomyopathy: insights into pathophysiology, diagnosis and clinical management.
    J Mol Cell Cardiol. 2025;206:55-69.
    PubMed         Abstract available
    
    

    
    Lancet

44. OSTROMINSKI JW, Cheng AYY, Nelson AJ, Neuen BL, et al
    Cardiovascular, kidney, and metabolic health: an actionable vision for heart failure prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01384-4. doi: 10.1016/S0140-6736(25)01384.
    PubMed         Abstract available
    
    
45. UDELL JA, Bahit MC, Campbell P, Butler J, et al
    Prevention of heart failure after acute myocardial infarction.
    Lancet. 2025 Aug 28:S0140-6736(25)01394-7. doi: 10.1016/S0140-6736(25)01394.
    PubMed         Abstract available
    
    
46. KHAN SS, Berwanger O, Fiuzat M, McMurray JJ, et al
    Prioritising the primary prevention of heart failure.
    Lancet. 2025 Aug 28:S0140-6736(25)01393-5. doi: 10.1016/S0140-6736(25)01393.
    PubMed         Abstract available
    
    
47. THE LANCET
    Heart failure: time to prioritise prevention.
    Lancet. 2025 Aug 28:S0140-6736(25)01775-1. doi: 10.1016/S0140-6736(25)01775.
    PubMed        
    
    
48. BHATT AS, Vardeny O
    Influenza vaccination in heart failure: a shot worth taking?
    Lancet. 2025 Aug 28:S0140-6736(25)01679-4. doi: 10.1016/S0140-6736(25)01679.
    PubMed        
    
    
49. ANDERSON CS, Hua C, Wang Z, Wang C, et al
    Influenza vaccination to improve outcomes for patients with acute heart failure (PANDA II): a multiregional, seasonal, hospital-based, cluster-randomised, controlled trial in China.
    Lancet. 2025 Aug 28:S0140-6736(25)01485-0. doi: 10.1016/S0140-6736(25)01485.
    PubMed         Abstract available
    
    
50. ZANNAD F, O'Connor CM, Butler J, McMullan CJ, et al
    Vericiguat for patients with heart failure and reduced ejection fraction across the risk spectrum: an individual participant data analysis of the VICTORIA and VICTOR trials.
    Lancet. 2025 Aug 29:S0140-6736(25)01682-4. doi: 10.1016/S0140-6736(25)01682.
    PubMed         Abstract available
    
    
51. BUTLER J, McMullan CJ, Anstrom KJ, Barash I, et al
    Vericiguat in patients with chronic heart failure and reduced ejection fraction (VICTOR): a double-blind, placebo-controlled, randomised, phase 3 trial.
    Lancet. 2025 Aug 29:S0140-6736(25)01665-4. doi: 10.1016/S0140-6736(25)01665.
    PubMed         Abstract available
    
    
52. KOHSAKA S, Heidenreich PA
    Vericiguat across the heart failure spectrum.
    Lancet. 2025 Aug 29:S0140-6736(25)01765-9. doi: 10.1016/S0140-6736(25)01765.
    PubMed        
    
    

    
    N Engl J Med

53. MUNKHAUGEN J, Kristensen AMD, Halvorsen S, Holmager T, et al
    Beta-Blockers after Myocardial Infarction in Patients without Heart Failure.
    N Engl J Med. 2025 Aug 30. doi: 10.1056/NEJMoa2505985.
    PubMed         Abstract available
    
    

    
    PLoS One

54. KANAPARTHY NS, Possick S, Teng W, Maulion C, et al
    Impact of clinical pathways on enhancing compliance with evidence-based therapies for Heart failure with reduced ejection fraction-A retrospective cohort study.
    PLoS One. 2025;20:e0330188.
    PubMed         Abstract available
    
    
55. GAO Z, Liu X, Kang Y, Hu P, et al
    Explainable mortality prediction models incorporating social health determinants and physical frailty for heart failure patients.
    PLoS One. 2025;20:e0327979.
    PubMed         Abstract available
    
    
56. DU M, He S, Liu J, Yuan L, et al
    Uncovering key biomarkers, potential therapeutic targets and development of deep learning model in heart failure.
    PLoS One. 2025;20:e0330780.
    PubMed         Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Chronic Heart Failure is free of charge.